Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
SRPT

Sarepta

$28.68

0.4 (1.41%)

07:05
02/22/17
02/22
07:05
02/22/17
07:05
Recommendations
Sarepta analyst commentary  »

Sarepta has chance to add…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

Yesterday
SRPT

Sarepta

$28.28

0.31 (1.11%)

, GILD

Gilead

$69.85

-0.46 (-0.65%)

09:47
02/21/17
02/21
09:47
02/21/17
09:47
Recommendations
Sarepta, Gilead analyst commentary  »

Sarepta sale of voucher…

SRPT

Sarepta

$28.28

0.31 (1.11%)

GILD

Gilead

$69.85

-0.46 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 17

    Mar

  • 01

    Apr

SRPT

Sarepta

$28.28

0.31 (1.11%)

, GILD

Gilead

$69.85

-0.46 (-0.65%)

08:16
02/21/17
02/21
08:16
02/21/17
08:16
Hot Stocks
Sarepta sells Gilead rare disease review voucher for $125M »

Sarepta Therapeutics…

SRPT

Sarepta

$28.28

0.31 (1.11%)

GILD

Gilead

$69.85

-0.46 (-0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 06

    Mar

  • 17

    Mar

  • 01

    Apr

SRPT

Sarepta

$28.28

0.31 (1.11%)

07:00
02/21/17
02/21
07:00
02/21/17
07:00
Hot Stocks
Sarepta agrees to sale of priority review voucher for $125M »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

Friday
SRPT

Sarepta

$27.97

0.06 (0.21%)

12:46
02/17/17
02/17
12:46
02/17/17
12:46
Options
Sarepta call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 28

    Feb

Over a week ago
SRPT

Sarepta

$27.67

-0.16 (-0.57%)

10:12
02/14/17
02/14
10:12
02/14/17
10:12
Periodicals
Sarepta 'dragged down unfairly' with Marathon, Feuerstein says »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SRPT

Sarepta

$27.83

-1.51 (-5.15%)

15:23
02/13/17
02/13
15:23
02/13/17
15:23
Periodicals
Marathon Pharma to pause launch of DMD treatment, CureDuchenne says »

Nonprofit organization…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SRPT

Sarepta

$27.83

-1.51 (-5.15%)

13:56
02/13/17
02/13
13:56
02/13/17
13:56
Recommendations
Sarepta analyst commentary  »

Credit Suisse says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SRPT

Sarepta

$27.83

-1.51 (-5.15%)

13:40
02/13/17
02/13
13:40
02/13/17
13:40
Recommendations
Sarepta analyst commentary  »

Sarepta shares defended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SRPT

Sarepta

$29.34

0.08 (0.27%)

18:45
02/09/17
02/09
18:45
02/09/17
18:45
Hot Stocks
Marathon confirms FDA approves Emflaza for Duchenne muscular dystrophy »

Marathon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.